-- Robert Preidt
MONDAY, Nov. 7 (HealthDay News) -- An investigational drug
called pridopidine seems an effective and safe treatment for people
with the progressive movement disorder Huntington's disease,
Huntington's patients have an imbalance in the signaling
chemical dopamine. The new drug stabilizes dopamine signaling in
areas of the brain that control movement and coordination.
According to the study authors, this is the first drug shown to
improve patients' loss of ability to move their muscles
voluntarily. The only drug currently approved for Huntington's is
tetrabenazine, which treats only involuntary movements and can
cause serious side effects.
The results of the phase 3 clinical trial, conducted by Spanish
researchers led by Dr. Justo Garcia de Yebenes, of the department
of neurology, Hospital Ramon y Cajal in Madrid, appear in the Nov.
7 online edition of
The Lancet Neurology.
The study included 437 Huntington's disease patients from eight
European countries. The participants took either pridopidine (45
milligrams once daily or 45 mg twice daily) or a placebo for 26
After six months of treatment, patients taking the higher dose
of pridopidine showed improvements in motor function --
specifically in eye and hand movements, involuntary muscle
contractions (dystonia), and gait and balance -- compared with
patients taking the placebo.
More than 70 percent of the patients taking the higher dose of
the drug showed a significant benefit, according to the
researchers. Side effects among patients taking the drug were
similar to the placebo group.
"Pridopidine has the potential to complement available treatments by improving a different range of motor deficits. Its lack of severe side-effects . . . suggests that pridopidine might be useful even for those patients who are treated at sites that are not centers of excellence for Huntington's disease," the researchers concluded.
One U.S. neurologist agreed that the drug seems promising
against a disease with few treatment options.
"There has been a great deal of attention for this drug, as it is one of the few molecules that in preliminary studies was found to have some efficacy in Huntington's disease," said Dr. Alessandro Di Rocco, professor in the department of neurology and chief of the division of movement disorders at NYU Langone Medical Center in New York City.
"However, this is the first large study to show evidence of a positive result in treating the motor symptoms of this devastating disease. And, though the compound is apparently well tolerated without significant side effects, the benefit is modest and limited to the motor symptoms of the disease and it is unknown how long the improvement observed could last," he added.
Still, pridopidine does not get at the underlying cause of
Huntington's disease, Di Rocco said.
"Unfortunately, Huntington's is a progressive disease and this drug is not a treatment of the disease itself but only improves some of its symptoms," he explained. "Nevertheless, it is a welcome addition because there is very little else yet available to treat the symptoms. The challenge for scientists and clinicians is to discover therapies that actually slows or halts the progression of the disease."
Another expert agreed that new treatment options for patients
are sorely needed.
"A well-tolerated drug that produces even small benefits for patients with Huntington's disease would be a very welcome addition to the currently available treatments for this debilitating disorder," Andrew Feigin, from The Feinstein Institute for Medical Research in New York City, wrote in an accompanying commentary.
The study was funded by European pharmaceuticals company
We Move has more about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.